Expression of melanoma-associated antigens in melanoma cell cultures. 2005

Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. mirjana.urosevic@usz.ch

The efficiency of melanoma immunotherapy appears to depend on both melanoma- and immune system-specific factors. Melanoma-specific factors include melanoma-associated antigen (MAA) expression as well as HLA class I molecule expression. We investigated the expression of five MAA - Melan-A/MART-1, tyrosinase, gp100, MAGE-1 and MAGE-3 - by means of FACS analysis in 50 melanoma cell cultures and compared them to the cultures of human foreskin-derived melanocytes and melanoma cell line UKRV-Mel2. Melan-A, tyrosinase and gp100 expression was frequently reduced in melanoma cell cultures, compared to that in foreskin melanocytes, whereas MAGE-1 and MAGE-3 expression showed variable degree of upregulation, compared to that in foreskin melanocytes. The expression of all tested MAA demonstrated high interindividual variability. We further show that cell cultures derived from the same tissue sample are oligoclonal in nature, by demonstrating the presence of up to three cell populations bearing distinct MAA profile. Analysing samples derived from the same patient but each at a different time point, we show that MAA expression profile changes over time either in positive (increase) or in negative (decrease) direction. Finally, we demonstrate that brain metastasis-derived cell cultures significantly overexpress Melan-A and MAGE-3, compared to primary tumours and other metastatic sites (P-value range: 0.05-0.001). Elucidation of the MAA expression patterns and the kinetics within the same patient as well as during the course of the disease may help improve current and develop new immunotherapeutic strategies.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females

Related Publications

Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
June 2001, Melanoma research,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
February 2008, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
August 1998, Archives of dermatological research,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
March 2000, Journal of cellular physiology,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
August 2002, Experimental dermatology,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
January 1981, Journal of immunology (Baltimore, Md. : 1950),
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
March 2000, Journal of cellular physiology,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
June 1987, Current eye research,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
January 2005, Investigative ophthalmology & visual science,
Mirjana Urosevic, and Bettina Braun, and Jörg Willers, and Günter Burg, and Reinhard Dummer
July 1998, Journal of cutaneous pathology,
Copied contents to your clipboard!